TrialDiabetes, obesity & metabolism2016

A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).

K M Dungan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.